Drug intelligence / Profile preview

Calmatrol

Development stage
Unknown
Lead developer
Goldman Pharmaceutical Group
Administration
Oral
01

Overview

Calmatrol is a **non-specific brand name** that refers to at least two distinct marketed products rather than one uniquely identifiable drug. One Calmatrol product is a veterinary over-the-counter oral medication distributed by Goldman Pharmaceutical Group whose active pharmaceutical ingredient is **diphenhydramine**, an H1 histamine receptor antagonist used in dogs for relief of occasional restlessness, hyperactivity, destructive behavior, and anxiety associated with noise, environmental changes, loneliness, and stress. A separate Calmatrol product marketed by Ortho Molecular Products is a **multi-ingredient dietary supplement** for human use containing herbal ingredients including **valerian root**, promoted for sleep and anxiety support. Because these are different formulations, indications, species, and regulatory categories, the exact identity of \"Calmatrol\" cannot be resolved to a single drug record without choosing one of these products specifically.

Brand names
Calmatrol
02

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Calmatrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calmatrol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call